Marleen Keyaerts

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7179972/publications.pdf

Version: 2024-02-01

61 papers	2,734 citations	201674 27 h-index	182427 51 g-index
61 all docs	61 docs citations	61 times ranked	3142 citing authors

#	Article	IF	Citations
1	Phase I Study of ⁶⁸Ga-HER2-Nanobody for PET/CT Assessment of HER2 Expression in Breast Carcinoma. Journal of Nuclear Medicine, 2016, 57, 27-33.	5.0	317
2	Comparison of the Biodistribution and Tumor Targeting of Two ^{99m}Tc-Labeled Anti-EGFR Nanobodies in Mice, Using Pinhole SPECT/Micro-CT. Journal of Nuclear Medicine, 2008, 49, 788-795.	5.0	194
3	Synthesis, Preclinical Validation, Dosimetry, and Toxicity of ⁶⁸Ga-NOTA-Anti-HER2 Nanobodies for iPET Imaging of HER2 Receptor Expression in Cancer. Journal of Nuclear Medicine, 2013, 54, 776-784.	5.0	173
4	SPECT Imaging with 99mTc-Labeled EGFR-Specific Nanobody for In Vivo Monitoring of EGFR Expression. Molecular Imaging and Biology, 2008, 10, 167-175.	2.6	158
5	HIV-1 Lentiviral Vector Immunogenicity Is Mediated by Toll-Like Receptor 3 (TLR3) and TLR7. Journal of Virology, 2010, 84, 5627-5636.	3.4	129
6	Targeted alpha therapy using short-lived alpha-particles and the promise of nanobodies as targeting vehicle. Expert Opinion on Biological Therapy, 2016, 16, 1035-1047.	3.1	119
7	Same-Day Imaging Using Small Proteins: Clinical Experience and Translational Prospects in Oncology. Journal of Nuclear Medicine, 2018, 59, 885-891.	5.0	101
8	Immunogenicity Risk Profile of Nanobodies. Frontiers in Immunology, 2021, 12, 632687.	4.8	97
9	Non-invasive assessment of murine PD-L1 levels in syngeneic tumor models by nuclear imaging with nanobody tracers. Oncotarget, 2017, 8, 41932-41946.	1.8	95
10	Undetectable circulating tumor DNA (ctDNA) levels correlate with favorable outcome in metastatic melanoma patients treated with anti-PD1 therapy. Journal of Translational Medicine, 2019, 17, 303.	4.4	89
11	The Next-Generation Immune Checkpoint LAG-3 and Its Therapeutic Potential in Oncology: Third Timeâ€™s a Charm. International Journal of Molecular Sciences, 2021, 22, 75.	4.1	87
12	Bioluminescence imaging: looking beyond the light. Trends in Molecular Medicine, 2012, 18, 164-172.	6.7	85
13	Noninvasive imaging of the PD-1:PD-L1 immune checkpoint: Embracing nuclear medicine for the benefit of personalized immunotherapy. Theranostics, 2018, 8, 3559-3570.	10.0	85
14	Dynamic bioluminescence imaging for quantitative tumour burden assessment using IV or IP administration of d-luciferin: effect on intensity, time kinetics and repeatability of photon emission. European Journal of Nuclear Medicine and Molecular Imaging, 2008, 35, 999-1007.	6.4	84
15	Theranostics in immuno-oncology using nanobody derivatives. Theranostics, 2019, 9, 7772-7791.	10.0	83
16	Clinical Translation of [68Ga]Ga-NOTA-anti-MMR-sdAb for PET/CT Imaging of Protumorigenic Macrophages. Molecular Imaging and Biology, 2019, 21, 898-906.	2.6	69
17	Phase I Trial of ¹³¹I-GMIB-Anti-HER2-VHH1, a New Promising Candidate for HER2-Targeted Radionuclide Therapy in Breast Cancer Patients. Journal of Nuclear Medicine, 2021, 62, 1097-1105.	5.0	67
18	Correlation Between Epidermal Growth Factor Receptor-Specific Nanobody Uptake and Tumor Burden: A Tool for Noninvasive Monitoring of Tumor Response to Therapy. Molecular Imaging and Biology, 2011, 13, 940-948.	2.6	51

#	Article	IF	Citations
19	Evaluating a Single Domain Antibody Targeting Human PD-L1 as a Nuclear Imaging and Therapeutic Agent. Cancers, 2019, 11, 872.	3.7	50
20	18F-FDG PET/CT based spleen to liver ratio associates with clinical outcome to ipilimumab in patients with metastatic melanoma. Cancer Imaging, 2020, 20, 36.	2.8	46
21	Noninvasive Imaging of the Immune Checkpoint LAG-3 Using Nanobodies, from Development to Pre-Clinical Use. Biomolecules, 2019, 9, 548.	4.0	43
22	Preclinical Targeted Î±- and Î²â^'-Radionuclide Therapy in HER2-Positive Brain Metastasis Using Camelid Single-Domain Antibodies. Cancers, 2020, 12, 1017.	3.7	43
23	Labeling of Anti-HER2 Nanobodies with Astatine-211: Optimization and the Effect of Different Coupling Reagents on Their in Vivo Behavior. Molecular Pharmaceutics, 2019, 16, 3524-3533.	4.6	42
24	Anti-Human PD-L1 Nanobody for Immuno-PET Imaging: Validation of a Conjugation Strategy for Clinical Translation. Biomolecules, 2020, 10, 1388.	4.0	42
25	Inhibition of Firefly Luciferase by General Anesthetics: Effect on In Vitro and In Vivo Bioluminescence Imaging. PLoS ONE, 2012, 7, e30061.	2.5	40
26	Genome-wide Computational Analysis Reveals Cardiomyocyte-specific Transcriptional Cis-regulatory Motifs That Enable Efficient Cardiac Gene Therapy. Molecular Therapy, 2015, 23, 43-52.	8.2	36
27	Next-generation muscle-directed gene therapy by in silico vector design. Nature Communications, 2019, 10, 492.	12.8	35
28	Single-Domain Antibody Nuclear Imaging Allows Noninvasive Quantification of LAG-3 Expression by Tumor-Infiltrating Leukocytes and Predicts Response of Immune Checkpoint Blockade. Journal of Nuclear Medicine, 2021, 62, 1638-1644.	5.0	26
29	A Comprehensive Analysis of Baseline Clinical Characteristics and Biomarkers Associated with Outcome in Advanced Melanoma Patients Treated with Pembrolizumab. Cancers, 2021, 13, 168.	3.7	24
30	Perforin and Granzyme B Expressed by Murine Myeloid-Derived Suppressor Cells: A Study on Their Role in Outgrowth of Cancer Cells. Cancers, 2019, 11, 808.	3.7	22
31	Plasma Protein Binding of Luciferase Substrates Influences Sensitivity and Accuracy of Bioluminescence Imaging. Molecular Imaging and Biology, 2011, 13, 59-66.	2.6	17
32	Single Domain Antibody-Mediated Blockade of Programmed Death-Ligand 1 on Dendritic Cells Enhances CD8 T-cell Activation and Cytokine Production. Vaccines, 2019, 7, 85.	4.4	17
33	A versatile T cell-based assay to assess therapeutic antigen-specific PD-1-targeted approaches. Oncotarget, 2018, 9, 27797-27808.	1.8	17
34	Site-Specific Radiolabeling of a Human PD-L1 Nanobody via Maleimideâ€“Cysteine Chemistry. Pharmaceuticals, 2021, 14, 550.	3.8	15
35	The Prognostic Value of CD206 in Solid Malignancies: A Systematic Review and Meta-Analysis. Cancers, 2021, 13, 3422.	3.7	15
36	Antigen-presenting cell-targeted lentiviral vectors do not support the development of productive T-cell effector responses: implications for in vivo targeted vaccine delivery. Gene Therapy, 2017, 24, 370-375.	4.5	11

#	Article	IF	Citations
37	Formatting and gene-based delivery of a human PD-L1 single domain antibody for immune checkpoint blockade. Molecular Therapy - Methods and Clinical Development, 2021, 22, 172-182.	4.1	11
38	Regional quantitative analysis of small animal myocardial sympathetic innervation and initial application in streptozotocin induced diabetes. Contrast Media and Molecular Imaging, 2009, 4, 174-182.	0.8	10
39	123I-2-iodo-tyrosine, a new tumour imaging agent: human biodistribution, dosimetry and initial clinical evaluation in glioma patients. European Journal of Nuclear Medicine and Molecular Imaging, 2007, 34, 994-1002.	6.4	9
40	The Road to Personalized Myeloma Medicine: Patient-specific Single-domain Antibodies for Anti-idiotypic Radionuclide Therapy. Molecular Cancer Therapeutics, 2022, 21, 159-169.	4.1	9
41	Computer-aided detection and segmentation of malignant melanoma lesions on whole-body <mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" altimg="si2.svg"><mml:msup><mml:mrow /><mml:mn>18</mml:mn></mml:msup></mml:math>F-FDG PET/CT using an interpretable deep learning approach. Computer Methods and Programs in Biomedicine, 2022, 221, 106902.	4.7	9
42	The role of chemotherapy in the treatment of low-grade glioma. A review of the literature. Acta Neurologica Belgica, 2005, 105, 137-43.	1.1	7
43	Intra-individual comparison of the human biodistribution and dosimetry of the D and L isomers of 2-[123I]iodo-phenylalanine. Nuclear Medicine Communications, 2007, 28, 823-828.	1.1	6
44	Air Leaks Localized With Lung Ventilation SPECT. Clinical Nuclear Medicine, 2012, 37, 1182-1183.	1.3	6
45	Adjuvant-Enhanced mRNA Vaccines. Methods in Molecular Biology, 2017, 1499, 179-191.	0.9	6
46	Phase I results of CAM-H2: Safety profile and tumor targeting in patients.. Journal of Clinical Oncology, 2018, 36, e13017-e13017.	1.6	6
47	Evaluation of single domain antibodies as nuclear tracers for imaging of the immune checkpoint receptor human lymphocyte activation gene-3 in cancer. EJNMMI Research, 2021, 11, 115.	2.5	5
48	Targeted Radionuclide Therapy with Low and High-Dose Lutetium-177â€“Labeled Single Domain Antibodies Induces Distinct Immune Signatures in a Mouse Melanoma Model. Molecular Cancer Therapeutics, 2022, 21, 1136-1148.	4.1	5
49	Early Reassessment of Total Metabolic Tumor Volume on FDG-PET/CT in Advanced Melanoma Patients Treated with Pembrolizumab Predicts Long-Term Outcome. Current Oncology, 2021, 28, 1630-1640.	2.2	4
50	Lyophilization of NOTA-sdAbs: First step towards a cold diagnostic kit for 68Ga-labeling. European Journal of Pharmaceutics and Biopharmaceutics, 2021, 166, 194-204.	4.3	4
51	Baseline total metabolic tumor volume assessed by 18FDG-PET/CT predicts outcome in advanced melanoma patients treated with pembrolizumab. Annals of Oncology, 2018, 29, x7.	1.2	3
52	68Ga-Labeling: Laying the Foundation for an Anti-Radiolytic Formulation for NOTA-sdAb PET Tracers. Pharmaceuticals, 2021, 14, 448.	3.8	3
53	Preliminary In Vivo Evaluation of [¹³¹I]-2-Iodo-<scp>D</scp>-Phenylalanine as a Potential Radionuclide Therapeutic Agent in R1M-Fluc Rhabdomyosarcoma Tumor-Bearing NuNu Mice Using Bioluminescent Imaging. Cancer Biotherapy and Radiopharmaceuticals, 2010, 25, 225-231.	1.0	2
54	Baseline biomarkers correlated with outcome in advanced melanoma treated with pembrolizumab monotherapy.. Journal of Clinical Oncology, 2020, 38, e22041-e22041.	1.6	2

#	Article	IF	Citations
55	Erdheim-Chester disease detected with 99MTC MDP bone SPECT/CT. Journal of the Belgian Society of Radiology, 2015, 95, 245.	0.2	2
56	Port-site metastasis after explorative laparoscopy for an incidental appendiceal mucinous cystadenocarcinoma detected with FDG PET/CT. Journal of the Belgian Society of Radiology, 2015, 96, 43.	0.2	1
57	Undetectable thyroglobulin makes 123I whole-body scan and stimulated thyroglobulin obsolete in follow-up care of differentiated thyroid cancer: a retrospective study. Thyroid Research, 2021, 14, 23.	1.5	0
58	Agenesis of the pubic symphysis detected with SPECT-CT. Journal of the Belgian Society of Radiology, 2015, 94, 97.	0.2	0
59	Selective spleen SPECT/CT. Journal of the Belgian Society of Radiology, 2015, 94, 353.	0.2	0
60	Nanobody-based PET/CT imaging of HER2 expression in breast carcinoma: Phase I results and potential to assess tumor heterogeneity.. Journal of Clinical Oncology, 2015, 33, e11600-e11600.	1.6	0
61	Abstract P3-02-05: Assessment of repeatability and uptake quantification of 68GaNOTA-anti-HER2 sdAb PET/CT in patients with locally advanced or metastatic breast cancer. Cancer Research, 2022, 82, P3-02-05-P3-02-05.	0.9	0